Current management of cerebral gliomas

Jeffree, Rosalind L.

doi:10.31128/ajgp-09-19-5063

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chunzhang Yang from the National Institutes of Health presented work on targeting IDH1‐mutant glioma stem cells. Glioma is the most frequent type of primary central nervous system tumor, and outcomes are typically very poor 145 . Glioma is a highly heterogenous disease.…”

Section: Targeting Idh‐mutant Glioblastomamentioning

confidence: 99%

Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report

Cable¹,

Pei

Reíd

et al. 2021

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The test for the cancer stem cell (CSC) hypothesis is to find a target expressed on all, and only CSCs in a patient tumor, then eliminate all cells with that target that eliminates the cancer. That test has not yet been achieved, but CSC diagnostics and targets found on CSCs and some other cells have resulted in a few clinically relevant therapies. However, it has become apparent that eliminating the subset of tumor cells characterized by self‐renewal properties is essential for long‐term tumor control. CSCs are able to regenerate and initiate tumor growth, recapitulating the heterogeneity present in the tumor before treatment. As great progress has been made in identifying and elucidating the biology of CSCs as well as their interactions with the tumor microenvironment, the time seems ripe for novel therapeutic strategies that target CSCs to find clinical applicability. On May 19–21, 2021, researchers in cancer stem cells met virtually for the Keystone eSymposium “Cancer Stem Cells: Advances in Biology and Clinical Translation” to discuss recent advances in the understanding of CSCs as well as clinical efforts to target these populations.

show abstract

Section: Targeting Idh‐mutant Glioblastomamentioning

confidence: 99%

Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report

Cable¹,

Pei

Reíd

et al. 2021

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…Glioblastoma (GBM) is the most common type of brain tumor in adults. Despite aggressive treatment, patient prognosis remains poor 1,2 . The majority of GBM patients experience recurrences within 6 to 9 months from diagnosis 3–5 .…”

Section: Introductionmentioning

confidence: 99%

“…Despite aggressive treatment, patient prognosis remains poor. 1 , 2 The majority of GBM patients experience recurrences within 6 to 9 months from diagnosis. 3 , 4 , 5 During treatment and follow‐up assessments, GBM patients' response is monitored mainly using imaging techniques.…”

Section: Introductionmentioning

confidence: 99%

Proteome profiling of salivary small extracellular vesicles in glioblastoma patients

Bark

Lima

Zhang

et al. 2023

Cancer

View full text Add to dashboard Cite

BackgroundExtracellular vesicles (EVs) play a critical role in intercellular communication under physiological and pathological conditions, including cancer. EVs cargo reflects their cell of origin, suggesting their utility as biomarkers. EVs are detected in several biofluids, and their ability to cross the blood–brain barrier has highlighted their potential as prognostic and diagnostic biomarkers in gliomas, including glioblastoma (GBM). Studies have demonstrated the potential clinical utility of plasma‐derived EVs in glioma. However, little is known about the clinical utility of saliva‐derived EVs in GBM.MethodsSmall EVs were isolated from whole mouth saliva of GBM patients pre‐ and postoperatively. Isolation was performed using differential centrifugation and/or ultracentrifugation. EVs were characterized by concentration, size, morphology, and EVs cell‐surface protein markers. Protein cargo in EVs was profiled using mass spectrometry.ResultsThere were no statistically significant differences in size and concentration of EVs derived from pre‐ and post GBM patients' saliva samples. A higher number of proteins were detected in preoperative samples compared to postoperative samples. The authors found four highly abundant proteins (aldolase A, 14‐3‐3 protein ε, enoyl CoA hydratase 1, and transmembrane protease serine 11B) in preoperative saliva samples from GBM patients with poor outcomes. Functional enrichment analysis of pre‐ and postoperative saliva samples showed significant enrichment of several pathways, including those related to the immune system, cell cycle and programmed cell death.ConclusionsThis study, for the first time, demonstrates the feasibility of isolating and characterizing small EVs from pre‐ and postoperative saliva samples from GBM patients. Preliminary findings encourage further large cohort validation studies on salivary small EVs to evaluate prognosis in GBM.

show abstract

Current management of cerebral gliomas

Cited by 2 publications

References 19 publications

Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report

Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report

Proteome profiling of salivary small extracellular vesicles in glioblastoma patients

Contact Info

Product

Resources

About